JP2010538093A - シソ科ファミリーのセイタカナミキソウのエストロゲン性抽出物およびその使用 - Google Patents
シソ科ファミリーのセイタカナミキソウのエストロゲン性抽出物およびその使用 Download PDFInfo
- Publication number
- JP2010538093A JP2010538093A JP2010524197A JP2010524197A JP2010538093A JP 2010538093 A JP2010538093 A JP 2010538093A JP 2010524197 A JP2010524197 A JP 2010524197A JP 2010524197 A JP2010524197 A JP 2010524197A JP 2010538093 A JP2010538093 A JP 2010538093A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- family
- treats
- prevents
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 241000207923 Lamiaceae Species 0.000 title claims abstract description 55
- 230000001076 estrogenic effect Effects 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 86
- 239000000262 estrogen Substances 0.000 claims abstract description 76
- 229940011871 estrogen Drugs 0.000 claims abstract description 75
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 65
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 52
- 230000004044 response Effects 0.000 claims abstract description 43
- 206010067572 Oestrogenic effect Diseases 0.000 claims abstract description 27
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 22
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 18
- 206010046766 uterine cancer Diseases 0.000 claims abstract description 17
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 13
- 241000894007 species Species 0.000 claims abstract description 12
- 108010038795 estrogen receptors Proteins 0.000 claims description 108
- 239000000203 mixture Substances 0.000 claims description 54
- 241000196324 Embryophyta Species 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 47
- 208000033830 Hot Flashes Diseases 0.000 claims description 46
- 206010060800 Hot flush Diseases 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 238000000605 extraction Methods 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 32
- 206010020718 hyperplasia Diseases 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000002609 medium Substances 0.000 claims description 26
- 108700008625 Reporter Genes Proteins 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 108700005075 Regulator Genes Proteins 0.000 claims description 9
- 206010006256 Breast hyperplasia Diseases 0.000 claims description 8
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002611 ovarian Effects 0.000 claims description 8
- 210000003101 oviduct Anatomy 0.000 claims description 8
- 208000025421 tumor of uterus Diseases 0.000 claims description 8
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 102000015694 estrogen receptors Human genes 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000005192 partition Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000005571 anion exchange chromatography Methods 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000005277 cation exchange chromatography Methods 0.000 claims description 2
- 238000002270 exclusion chromatography Methods 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 7
- 230000009826 neoplastic cell growth Effects 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000014493 regulation of gene expression Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 abstract description 27
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract description 9
- 230000001629 suppression Effects 0.000 abstract description 7
- 230000000638 stimulation Effects 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 241000218231 Moraceae Species 0.000 abstract 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 118
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 117
- 210000004027 cell Anatomy 0.000 description 114
- 102100038595 Estrogen receptor Human genes 0.000 description 102
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 75
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 72
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 68
- 239000000419 plant extract Substances 0.000 description 58
- 238000011282 treatment Methods 0.000 description 53
- 102100040247 Tumor necrosis factor Human genes 0.000 description 48
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 46
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 42
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 229940079593 drug Drugs 0.000 description 40
- 108060001084 Luciferase Proteins 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 229960001603 tamoxifen Drugs 0.000 description 34
- 230000004913 activation Effects 0.000 description 32
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 31
- 239000005089 Luciferase Substances 0.000 description 26
- 229960004622 raloxifene Drugs 0.000 description 26
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- 230000002265 prevention Effects 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 230000037361 pathway Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 102000006601 Thymidine Kinase Human genes 0.000 description 12
- 108020004440 Thymidine kinase Proteins 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 102100027584 Protein c-Fos Human genes 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 230000002357 endometrial effect Effects 0.000 description 10
- 229960005309 estradiol Drugs 0.000 description 10
- 229930182833 estradiol Natural products 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 9
- 230000001833 anti-estrogenic effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 206010022437 insomnia Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 239000000328 estrogen antagonist Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 229940106582 estrogenic substances Drugs 0.000 description 6
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003081 coactivator Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 201000008968 osteosarcoma Diseases 0.000 description 5
- 229930000223 plant secondary metabolite Natural products 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940046836 anti-estrogen Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000017807 phytochemicals Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000036299 sexual function Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000009164 estrogen replacement therapy Methods 0.000 description 3
- -1 ethyl ethyl Chemical group 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 2
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- FRIPRWYKBIOZJU-UHFFFAOYSA-N fluorone Chemical compound C1=CC=C2OC3=CC(=O)C=CC3=CC2=C1 FRIPRWYKBIOZJU-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001051083 Homo sapiens Galectin-12 Proteins 0.000 description 1
- 101001034009 Homo sapiens Glutamate receptor-interacting protein 1 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241001135786 Lactobacillus cerevisiae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
- 102100022935 Nuclear receptor corepressor 1 Human genes 0.000 description 1
- 101710153661 Nuclear receptor corepressor 1 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 101710159283 Vitellogenin-A2 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000007120 differential activation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97079307P | 2007-09-07 | 2007-09-07 | |
| PCT/US2008/075468 WO2009033075A1 (en) | 2007-09-07 | 2008-09-05 | ESTROGENIC EXTRACTS OF Scuttelaria barbata D. DON OF THE LABIATAE FAMILY AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538093A true JP2010538093A (ja) | 2010-12-09 |
| JP2010538093A5 JP2010538093A5 (https=) | 2011-04-14 |
Family
ID=40429380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524197A Pending JP2010538093A (ja) | 2007-09-07 | 2008-09-05 | シソ科ファミリーのセイタカナミキソウのエストロゲン性抽出物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9155770B2 (https=) |
| EP (1) | EP2190292A4 (https=) |
| JP (1) | JP2010538093A (https=) |
| AU (1) | AU2008296136A1 (https=) |
| CA (1) | CA2698747A1 (https=) |
| WO (1) | WO2009033075A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100303936A1 (en) * | 2009-04-28 | 2010-12-02 | Bionovo, Inc. A Delaware Corporation | Method of reducing fat accumulation and inducing weight loss |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069452A1 (en) * | 1999-05-17 | 2000-11-23 | Yoshio Takeda | Remedies for cancer and infection with helicobacter pylori and process for producing the same |
| WO2006107745A2 (en) * | 2005-04-01 | 2006-10-12 | Bionovo, Inc. | Composition for treatment of menopause |
| WO2007059149A2 (en) * | 2005-11-14 | 2007-05-24 | Bionovo, Inc. | Scutellaria barbata extract for the treatment of cancer |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2616328B1 (fr) | 1987-06-12 | 1990-03-02 | Moet Hennessy Rech | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant |
| JPH01175942A (ja) * | 1987-12-28 | 1989-07-12 | Sanyo Kokusaku Pulp Co Ltd | 抗ウイルス性医薬用組成物 |
| GB9103075D0 (en) | 1991-02-13 | 1991-03-27 | Washington Odur Ayuko | Trinitrobenzene derivatives and their therapeutic use |
| JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
| US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
| US5874084A (en) * | 1996-07-19 | 1999-02-23 | Yng-Wong; Quing Non | Using complex herbal formulations to treat hot flashes |
| KR100221762B1 (ko) | 1996-10-29 | 1999-09-15 | 이승기 | 에모딘의 항암제로서의 용도 |
| AU746946B2 (en) * | 1997-03-21 | 2002-05-09 | Shiseido Company Ltd. | Immunopotentiators |
| MC2441A1 (fr) | 1997-07-31 | 1998-03-11 | Exsymol Sa | Composition cosmétique utile notamment pour le blanchiment de la peau et agent inhibiteur de la mélanogénèse comprenant une telle composition cosmétique |
| CN1059117C (zh) | 1997-11-25 | 2000-12-06 | 董有本 | 蝎毒肿瘤丸及其制备方法 |
| FR2784294B1 (fr) | 1998-10-12 | 2000-11-17 | Oreal | Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique |
| US6304825B1 (en) * | 1999-01-19 | 2001-10-16 | Xerox Corporation | Rotary encoder error compensation system and method for photoreceptor surface motion sensing and control |
| FR2791573B1 (fr) * | 1999-03-30 | 2003-04-11 | Pf Medicament | Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate |
| JP2001122871A (ja) | 1999-10-26 | 2001-05-08 | Nippon Kayaku Co Ltd | エストロゲン様作用薬剤 |
| CN1294009A (zh) | 1999-10-28 | 2001-05-09 | 马金发 | 抗癌中药制剂及其置备方法 |
| DE10031650A1 (de) * | 2000-06-29 | 2002-01-17 | Schwabe Willmar Gmbh & Co | Verwendung von Extrakten aus Sophora flavescens oder Sophora subprostrata zur Prophylaxe und Therapie von Krankheitszuständen, die durch einen Mangel an Östrogenen oder durch andere hormonelle Dysregulationen verursacht werden |
| JP4693963B2 (ja) | 2000-07-12 | 2011-06-01 | 丸善製薬株式会社 | エストロゲン様作用剤、コラーゲン産生促進剤、及び線維芽細胞増殖剤 |
| US6238707B1 (en) * | 2000-10-11 | 2001-05-29 | Zhang Chun | Herbal hormone balance composition |
| JP2005501816A (ja) * | 2000-12-12 | 2005-01-20 | ワックヴォム リミテッド | Ｓｃｕｔｅｌｌａｒｉａｅｂａｒｂａｔａｅから単離された活性な画分を含む組成物および使用方法 |
| JP2002284696A (ja) | 2001-03-28 | 2002-10-03 | Doi Keiko | ウイルス、真菌その他の菌性疾患の治療方法 |
| US6551627B1 (en) | 2001-05-03 | 2003-04-22 | Holomed Pharmaceuticals, Ltd. | Medicinal herbal compounds for the prevention and treatment of diabetes |
| KR100456981B1 (ko) | 2001-07-14 | 2004-11-10 | (주) 메드빌 | 식물추출물을 포함하는 골다공증 예방 또는 치료용 조성물및 그 제조 방법 |
| US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| KR20030027208A (ko) | 2001-09-14 | 2003-04-07 | 주식회사 바이오딕스 | 생약을 함유하는 관절염 치료용 조성물 및 그 제조방법 |
| US6750248B2 (en) * | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
| JP2004155779A (ja) | 2002-10-16 | 2004-06-03 | Taisho Pharmaceut Co Ltd | 更年期症の予防・治療用経口組成物 |
| AU2002952453A0 (en) * | 2002-11-01 | 2002-11-21 | Novogen Research Pty Ltd | Aminated isoflavonoid derivatives and uses thereof |
| JP4474518B2 (ja) * | 2003-03-28 | 2010-06-09 | 学校法人日本大学 | ２−ヒドロキシイソフラバノンデヒドラターゼをコードするポリヌクレオチドおよびその応用 |
| WO2005044179A2 (en) * | 2003-06-27 | 2005-05-19 | Hong Kong University Of Science And Technology | Formulations containing astragalus extracts and uses thereof |
| ES2373663T3 (es) | 2003-09-08 | 2012-02-07 | Genyous Biomed International Inc. | Composiciones de extractos botánicos para terapia de cáncer. |
| US20050196409A1 (en) * | 2003-09-24 | 2005-09-08 | James Dao | Compositions of botanical extracts for treating malignancy-associated changes |
| US20050118290A1 (en) * | 2003-12-02 | 2005-06-02 | University Of Singapore | Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
| US20050208159A1 (en) * | 2004-03-16 | 2005-09-22 | Kang Kyung S | Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin |
| BRPI0510717B8 (pt) * | 2004-05-06 | 2021-05-25 | Bioresponse Llc | uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr) |
| US20050260285A1 (en) * | 2004-05-21 | 2005-11-24 | Dimateeo-Leggio Giovina | Healthy prostate formula |
| US7887851B2 (en) * | 2004-06-07 | 2011-02-15 | Kao Corporation | Aromatase activator |
| JP4939425B2 (ja) * | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス， インコーポレイテッド | 乳癌の治療反応の予後および予測の分子指標 |
| JP2008520588A (ja) * | 2004-11-18 | 2008-06-19 | ビオファーマコペ デジン アンテルナショナル インク． | 植物抽出物およびその皮膚科使用法 |
| KR100589050B1 (ko) | 2004-11-23 | 2006-06-14 | 인하대학교 산학협력단 | 황기 추출물 및 그로부터 분리한 이소플라보노이드계화합물을 유효성분으로 하는 관절염 예방 및 치료용 조성물 |
| WO2006062876A2 (en) * | 2004-12-09 | 2006-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| US7815949B2 (en) * | 2004-12-17 | 2010-10-19 | Bionovo, Inc. | Estrogenic extracts of Morus alba and uses thereof |
| JP2008524221A (ja) | 2004-12-17 | 2008-07-10 | バイオノボ・インコーポレーテッド | Ｅｐｉｍｅｄｉｕｍ属植物の抽出液を用いた方法 |
| AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CN100349577C (zh) * | 2005-08-25 | 2007-11-21 | 深圳海王药业有限公司 | 黄芩总黄酮提取物及黄芩苷在抗骨质疏松药物制备中的用途 |
| HRP20170103T1 (hr) * | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| CN101073600A (zh) | 2006-05-17 | 2007-11-21 | 赵赐安 | 一种治疗各种毒蛇咬伤的洗用解毒药 |
| BRPI0713198A2 (pt) | 2006-07-19 | 2012-10-16 | Osurf Ohio State University Res Foundation | modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos |
| US7381432B2 (en) * | 2006-09-19 | 2008-06-03 | Jose Angel Olalde | Menopause disorder synergistic phyto-nutraceutical composition |
| US20080319051A1 (en) * | 2007-06-22 | 2008-12-25 | Bionovo, Inc. | Liquiritigenin and derivatives as selective estrogen receptor beta agonists |
| US20090042818A1 (en) * | 2007-06-22 | 2009-02-12 | Bionovo, Inc. | Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists |
| WO2009021196A1 (en) * | 2007-08-08 | 2009-02-12 | Bionovo, Inc. | Extracts of ligustrum lucidum and uses thereof |
| JP2010539086A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのクズのエストロゲン性抽出物およびその使用 |
| WO2009033025A1 (en) * | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof |
| JP2010539085A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのキバナオウギのエストロゲン性抽出物およびその使用 |
| US20090258942A1 (en) * | 2008-04-14 | 2009-10-15 | Bionovo, Inc. | Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
| EP2310024A4 (en) * | 2008-05-06 | 2012-07-25 | Bionovo Inc | ESTROGENIC EXTRACTS FOR THE TREATMENT OF VAGINA AND VULVAATROPHY |
| EP2294402A2 (en) * | 2008-06-05 | 2011-03-16 | Bionovo Inc. | Method of quantification of multiple bioactives from botanical compositons |
| US20090312437A1 (en) * | 2008-06-06 | 2009-12-17 | Bionovo, Inc., A Delaware Corporation | Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions |
| WO2010053600A2 (en) * | 2008-06-13 | 2010-05-14 | Bionovo, Inc. | Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
-
2008
- 2008-09-05 US US12/205,710 patent/US9155770B2/en active Active
- 2008-09-05 JP JP2010524197A patent/JP2010538093A/ja active Pending
- 2008-09-05 EP EP08799252A patent/EP2190292A4/en not_active Withdrawn
- 2008-09-05 CA CA 2698747 patent/CA2698747A1/en not_active Abandoned
- 2008-09-05 WO PCT/US2008/075468 patent/WO2009033075A1/en not_active Ceased
- 2008-09-05 AU AU2008296136A patent/AU2008296136A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069452A1 (en) * | 1999-05-17 | 2000-11-23 | Yoshio Takeda | Remedies for cancer and infection with helicobacter pylori and process for producing the same |
| WO2006107745A2 (en) * | 2005-04-01 | 2006-10-12 | Bionovo, Inc. | Composition for treatment of menopause |
| WO2007059149A2 (en) * | 2005-11-14 | 2007-05-24 | Bionovo, Inc. | Scutellaria barbata extract for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| US9155770B2 (en) | 2015-10-13 |
| WO2009033075A1 (en) | 2009-03-12 |
| US20090068297A1 (en) | 2009-03-12 |
| AU2008296136A1 (en) | 2009-03-12 |
| EP2190292A4 (en) | 2012-12-26 |
| EP2190292A1 (en) | 2010-06-02 |
| CA2698747A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9339523B2 (en) | Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae family and uses thereof | |
| US9220740B2 (en) | Estrogenic extracts of Astragalus membranaceus fisch. bge. var. mongolicus bge. of the Leguminosae family and uses thereof | |
| JP2010539086A (ja) | マメ科ファミリーのクズのエストロゲン性抽出物およびその使用 | |
| US8092841B2 (en) | Estrogenic extracts of Ligustrum lucidum ait. of the oleaceae family and uses thereof | |
| JP2011516583A (ja) | エストロゲン受容体β介在疾患の治療のためのカリコシン及びその類似物質 | |
| JP2012529421A (ja) | エストロゲン受容体β媒介性疾患の治療のためのニアソールおよびその類似体 | |
| US20090297638A1 (en) | ESTROGENIC EXTRACTS OF Anemarrhena asphodeloides Bge. from the Liliaceae Family and USES THEREOF | |
| US9132161B2 (en) | Estrogenic extracts of Rheum palmatum L of the polygonaceae family and uses thereof | |
| US9155770B2 (en) | Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120814 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130129 |